FDA grants traditional approval to pirtobrutinib for BTK-inhibitor-pretreated CLL/SLL

Later-Stage HumanFDA-approved for the exact stated cancer/useNot addressed

The FDA granted traditional (full) approval to pirtobrutinib (Jaypirca), the first and only non-covalent (reversible) BTK inhibitor, for adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) previously treated with a covalent BTK inhibitor — converting the drug’s original December 2023 accelerated approval into a full approval on the strength of a randomized, confirmatory trial. The conversion was supported by the randomized, open-label, phase 3 BRUIN-CLL-321 trial (ClinicalTrials.gov NCT04666038; primary publication in the Journal of Clinical Oncology, DOI 10.1200/JCO-25-00166, PMID 40479620), which randomized 238 previously treated CLL/SLL patients. Progression-free survival — the trial’s primary endpoint — was significantly longer with pirtobrutinib: median 11.2 months versus 8.7 months with investigator’s choice of idelalisib plus rituximab or bendamustine plus rituximab (hazard ratio 0.58, P=.0105), a real, statistically significant improvement.

What This Means

In the randomized, phase 3 BRUIN-CLL-321 trial, pirtobrutinib -- the first and only non-covalent (reversible) BTK inhibitor -- significantly extended progression-free survival compared with standard chemoimmunotherapy options in patients with CLL/SLL that had already progressed on a covalent BTK inhibitor: median 11.2 months versus 8.7 months, converting the drug's original accelerated approval into a full, traditional FDA approval.

What This Doesn't Mean

This approval is specifically for patients whose disease has already progressed on or is intolerant to a COVALENT BTK inhibitor -- it is not a first-line CLL/SLL treatment, and this record makes no claim about pirtobrutinib's effect on overall survival, which was a secondary endpoint in this trial.

Why It Matters

A confirmed, randomized phase 3 trial converting an accelerated approval to full approval represents real, mature evidence for a genuinely novel drug class (non-covalent BTK inhibition) that can work even after a covalent BTK inhibitor has stopped working -- adding real depth to leukemia coverage on this site.

Promise & Proof

Proof — strength of the evidence 5 / 5

Base score from evidence stage: Later-Stage Human.
FDA-approved for the exact stated cancer/use.

Promise — potential significance if later evidence holds up 3 / 5

Baseline — a validly-evidenced story starts here; every further point below is an explicit, checkable reason.
The record includes substantive editorial reasoning about why this discovery matters.
A distinct follow-on/confirmatory study or trial is already cited as a secondary source — the field is already building on this finding.

These two ratings are automatically computed from this story's own structured evidence fields and are shown separately on purpose — they are never combined into one score. They describe this record, not a medical recommendation: they do not establish medical certainty, do not substitute for reading the cited sources, and are recalculated whenever the underlying evidence changes.

Population / Applicability

Studied in: Adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) previously treated with a covalent BTK inhibitor, randomized to pirtobrutinib or investigator's choice of idelalisib plus rituximab or bendamustine plus rituximab, in the randomized, open-label, phase 3 BRUIN-CLL-321 trial. (Adults)

Requires prior treatment with a covalent BTK inhibitor -- not appropriate as an initial CLL/SLL treatment. This record has not independently reviewed the full safety/tolerability profile, which should be added before publication.

Full evidence details

Study design: Randomized controlled trial
Sample size: 238

Funding & Conflicts

Sponsor/developer: Eli Lilly and Company (via its Loxo Oncology subsidiary) -- not independently confirmed against a primary corporate-disclosure document.

Regulatory status by jurisdiction

United States (FDA)

Status: FDA-approved for the exact stated cancer/use
Indication: Adults with relapsed or refractory CLL/SLL who have previously been treated with a covalent BTK inhibitor.
Decision date: 2025-12-03
Source: Regulator record (opens in a new tab)

Guideline positions

Guideline

Position: Not addressed
Last verified: 2026-08-13

Primary evidence supporting this story

Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321) (Journal of Clinical Oncology) (opens in a new tab) (Peer-reviewed paper) [Peer-reviewed] 10.1200/JCO-25-00166 Load-bearing source DOI 10.1200/JCO-25-00166, PMID 40479620
Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321) (Journal of Clinical Oncology). DOI 10.1200/JCO-25-00166, PMID 40479620.

Additional context

BRUIN-CLL-321 trial registry (opens in a new tab) (Clinical-trial registry) NCT04666038 NCT04666038
BRUIN-CLL-321 trial registry. NCT04666038.

Why Should I Trust This?

1 source at Tier 2 — Peer-reviewed primary research, trial registries, regulatory documents, official conference abstracts
Last reviewed: 2026-08-13

This panel summarizes real, checkable facts about this record's own sources and review status — it is not a trust score, and reading it is not a substitute for reading the cited sources yourself.

Discovery Timeline

Every recorded change to this record's content or publication status, in order.

2026-08-13 Status change — Status changed from "Legacy / Unverified" to "In editorial review".
2026-08-13 Status change — Status changed from "In editorial review" to "Verified".

Last reviewed 2026-08-13